KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Finished Goods (2019 - 2025)

Opko Health's Finished Goods history spans 7 years, with the latest figure at $44.0 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 36.16% year-over-year to $44.0 million; the TTM value through Dec 2025 reached $44.0 million, up 36.16%, while the annual FY2025 figure was $44.0 million, 36.16% up from the prior year.
  • Finished Goods reached $44.0 million in Q4 2025 per OPK's latest filing, up from $42.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $44.1 million in Q4 2021 to a low of $32.3 million in Q4 2024.
  • Average Finished Goods over 5 years is $37.9 million, with a median of $36.8 million recorded in 2022.
  • Peak YoY movement for Finished Goods: fell 15.8% in 2022, then skyrocketed 36.16% in 2025.
  • A 5-year view of Finished Goods shows it stood at $44.1 million in 2021, then dropped by 15.8% to $37.1 million in 2022, then dropped by 4.19% to $35.6 million in 2023, then fell by 9.2% to $32.3 million in 2024, then surged by 36.16% to $44.0 million in 2025.
  • Per Business Quant, the three most recent readings for OPK's Finished Goods are $44.0 million (Q4 2025), $42.3 million (Q3 2025), and $42.2 million (Q2 2025).